Application of Pharmacokinetic-Pharmacodynamic Modeling to Inform Translation of In Vitro NaV1.7 Inhibition to In Vivo Pharmacological Response in Non-human Primate.
Jeanine E BallardParul PallJoshua VardiganFuqiang ZhaoMarie A HolahanRichard KrausYuxing LiDarrell HenzeAndrea HoughtonChristopher S BurgeyChristopher GibsonPublished in: Pharmaceutical research (2020)
A staged approach to PK-PD modeling and simulation enabled integration of in vitro NaV1.7 potency, plasma protein binding, and pharmacokinetics to describe the exposure-response profile and inform future study design as the NaV1.7 inhibitor effort progressed through drug discovery.